Evaluation of pediatric rheumatology telehealth satisfaction during the COVID-19 pandemic

Table 1 Patient demographics, disease, and treatment characteristics

Variable	N = 248^a
Patient Age
≤ 5 years	35 (14.1%)
6–12 years	68 (27.4%)
13–17 years	118 (47.6%)
≥ 18 years	27 (10.9%)
Race
Caucasian	188 (75.8%)
African American	16 (6.5%)
Asian	17 (6.9%)
Other	27 (10.9%)
Condition
Juvenile idiopathic arthritis	83 (33.5%)
Systemic lupus erythematosus	16 (6.5%)
Inflammatory disease^b	40 (16.1%)
Amplified musculoskeletal pain	36 (14.5%)
Other/Unknown	73 (29.4%)
Rheumatologic diagnosis in the past 6 months	59 (23.8%)
Prescribed rheumatologic medication(s)	148 (59.7%)
Glucocorticoid therapy for rheumatologic condition	36 (14.5%)
Rheumatology new patient visit (n = 212)	85 (40.1%)

^aUnless otherwise indicated
^bDiagnoses included in the “inflammatory disease” category include Sjogren syndrome, vasculitis, juvenile dermatomyositis, chronic nonbacterial osteomyelitis, idiopathic uveitis, localized scleroderma, systemic sclerosis, Behcet syndrome, sarcoidosis, and periodic fever syndrome or auto-inflammatory disorder

ISSN: 1546-0096